

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Jean-Marie BUERSTEDDE *et al.*

Art Unit: To Be Assigned

Appln. No.: 10/590,211

Examiner: To Be Assigned

Filed: August 22, 2006

Atty. Docket: P30753US00/21027.002

Int'l Filing Date: February 23, 2005

For: Methods for Genetic Diversification in Gene Conversion Active Cells

**Information Disclosure Statement**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:


The attention of the Examiner is invited to the document listed on the attached Forms PTO/SB/08a and PTO/SB/08b. Copies of the listed documents are submitted herewith.

It is respectfully requested that the information above be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

**Certification and/or Fee**

Because this Information Disclosure Statement is being submitted before issuance of the first action on the merits of the above-captioned application, it is believed that no fee is due in conjunction with this filing.

Respectfully submitted,



Thomas E. Holsten (Reg. No. 46,098)

David R. Marsh (Reg. No. 41,408)

Arnold & Porter LLP

555 Twelfth Street, N.W.

Washington, DC 20004

Tel: 202-942-5000

Fax: 202-942-5999

Date: September 14, 2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/590,211
				Int'l Filing Date	February 23, 2005
				First Named Inventor	Jean-Marie BUERSTEDDE
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	1	of	2	Attorney Docket Number	P30753US00/21027.002

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	US-			
	B1	US-			
	C1	US-			
	D1	US-			
	E1	US-			
	F1	US-			
	G1	US-			
	H1	US-			
	I1	US-			
	J1	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	K1	WO 00/22111 A1	04-20-2000	Medical Research Council		✓
	L1	WO 02/100998 A2	12-19-20002	Medical Research Council		✓
	M1					
	N1					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/590,211
				Int'l Filing Date	February 23, 2005
				First Named Inventor	Jean-Marie BUERSTEDDE
				Art Unit	To Be Assigned
				Examiner Name	To Be Assigned
Sheet	2	of	2	Attorney Docket Number	P30753US00/21027.002

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A2	Arakawa <i>et al.</i> , "Immunoglobulin Gene Conversion: Insights from Bursal B Cells and the DT40 Cell Line," <i>Developmental Dynamics</i> , 229:458-464 (2004)	
	B2	Diaz <i>et al.</i> , "Evolution of Somatic Hypermutation and Gene Conversion in Adaptive Immunity," <i>Immunological Reviews</i> , 162:13-24 (1998)	
	C2	Sale <i>et al.</i> , "TdT-Accessible Breaks are Scattered over the Immunoglobulin V Domain in a Constitutively Hypermutating B Cell Line," <i>Immunity</i> , 9:859-869 (1998)	
	D2	Yélamos <i>et al.</i> , "Targeting of non-Ig Sequences in Place of the V Segment by Somatic Hypermutation," <i>Nature</i> , 376:225-229 (1995)	
	E2	International Search Report from PCT/EP2005/001897 (mailed Aug. 17, 2005)	
	F2		
	G2		
	H2		
	I2		
	J2		
	K2		
	L2		
	M2		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.